Pertuzumab protects the achilles' heel of trastuzumab--emtansine.


Journal Article

Trastuzumab emtansine (T-DM1) represents a significant advancement in the treatment of HER2(+) breast cancers. Its clinical efficacy however will be limited by the development of therapeutic resistance. In this report, the HER3 ligand neuregulin is shown to mediate T-DM1 resistance, which was overcome by administration of pertuzumab, a steric inhibitor of HER2 dimerization.

Full Text

Duke Authors

Cited Authors

  • Gwin, WR; Spector, NL

Published Date

  • January 15, 2014

Published In

Volume / Issue

  • 20 / 2

Start / End Page

  • 278 - 280

PubMed ID

  • 24240115

Pubmed Central ID

  • 24240115

International Standard Serial Number (ISSN)

  • 1078-0432

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-13-2626


  • eng

Conference Location

  • United States